|
Confirmed topics for 2007
Confirmed conference topics for the European Stem Cell & Regenerative Medicine Congress 2007 include:
-
Stem cells in drug discovery and development
-
Target identification and validation
-
Lead identification and optimisation
-
High through-put drug screening
-
Drug safety applications
-
Laying foundations for stem cell funding
-
Translational stem cell science – a roadmap to the clinic
-
Stem cell commercialisation - turning science into business
-
Negotiating the obstacles to clinical trial
-
Assessment of therapeutic potential
-
Core development and manufacturing expertise
Speakers and their application at a glance
Pharmaceutical
- Dr Ruth McKernan, Vice President, and Head of Discovery Biology, Pfizer Global Research and Development
- Professor Ian Cotgreave, Director of Molecular Toxicology, Safety Assessment, AstraZeneca
- Dr Christophe Labie, Group Leader, CNS Department, sanofi-aventis
- Dr Ignacio Munoz-Sanjuan, Senior Scientist, Amgen
Biotechnical
- Hugh Ilyine, Vice President and Chief Operating Officer, Stem Cell Sciences
- Christopher J Calhoun, Chief Executive Officer, Cytori Therapeutics
- Michael Hunt, Chief Executive Officer, ReNeuron
- Dr Thomas B Okarma, President and Chief Executive Officer, Geron
- Dr Michael West, President and Chief Scientific Officer, Advanced Cell Technology
- Dr John Sinden, Chief Scientific Officer, ReNeuron
- Dr Tim Allsopp, Chief Scientific Officer, Stem Cell Sciences
- Dr Geoff MacKay, President and Chief Executive Officer, Organogenesis
- Michael Siani-Rose, President and Founder, Theregen Corporation
- Professor Eldad Melamed, Chief Medical Advisor, Brainstorm Cell Therapeutics
- Dr Holly Atkinson, Director of Business Development, Brainstorm Cell Therapeutics
- Dr Alan Lewis, President and Chief Executive Officer, Novocell
- Dr Lilian Wikström, Head of Research, NeuroNova
- Bruce Cohen, President and Chief Executive Officer, Cellerant Therapeutics
- Dr Jon Tinsley, Head of Biology, VASTox
- Dr Yen Choo, Founder and Chief Executive Officer, Plasticell
- Dr Lauren E Black, Senior Scientific Advisor, Navigators, Preclinical Services, Charles River Laboratories
- Dr Jon Chesnut, Research and Development Manager, Invitrogen
- Dr Helmuth van Es, Chief Scientific Officer, Stem Cell Innovations
- Professor Lars E Sundstrom, Chief Scientific Officer, Capsant Neurotechnologies
- Dr Paul Rounding, Managing Director, Business Development & Operations, Artemis Pharmaceuticals
- Dr Paul Rodgers, Founder and Managing Director, Ithaka LifeSciences
- Dr Paul Kemp, Chief Scientific Officer, Intercytex
- Dr Madhusudan Peshwa, Vice President, Research and Development, MaxCyte
- Dr Valentin Fulga, Chief Executive Officer, TheraVitae
- Dr Elmar Burchardt, Vice President, Medical Affairs, Aastrom Biosciences
Academic / Clinical
- Dr Chris Mason, Director, Regenerative Medicine Bioprocessing Unit, University College London
- Dr Stephen L Minger, Director, Stem Cell Biology Laboratory, Wolfson Centre for Age-Related Diseases, King’s College London
- Professor Peter W Andrews, Professor of Biomedical Science, Department of Biomedical Science, University of Sheffield
- Dr Gabriela Gebrin Cezar, Assistant Professor, Department of Animal Science, University of Wisconsin-Madison
- Professor Oliver Brüstle, Director, Institute of Reconstructive Neurobiology, University of Bonn and Scientific Director, LIFE & BRAIN
- Professor Yann Barrandon, Joint Chair of Stem Cell Dynamics, Centre Hospitalier Universitaire Vaudois (CHUV) and Ecole Polytechnique Fédérale de Lausanne (EPFL)
- Dr Jan Matthias Braun, Coordinator, Regenerative Medicine Network, Leipzig-Halle Max Buerger Research Centre, University of Leipzig
Government / Regulatory
- Dr Octavi Quintana Trias, Director “Health”, Research DG, European Commission
- Dr Mark Bale, Head of Genetics Branch, Scientific Development & Bioethics Division, Department of Health, UK
- David Macauley, Chief Executive, UK Stem Cell Foundation
- Dr Frances Rawle, Programme Manager, Molecular and Cellular Medicine Board, Medical Research Council
- Dr Colin Miles, Head, Molecular & Cell Biology Branch, Science & Technology Group, BBSRC
- Dr Mark Walport, Director, The Wellcome Trust
Contract Manufacturing
- Dr Alan K Smith, President and Chief Operating Officer, Cognate BioServices
- Dr Robert A Preti, President and Chief Scientific Officer, Progenitor Cell Therapy
Venture Capital
- Greg A Bonfiglio, Managing Director, Partner, Proteus Venture Partners
- Linda Powers, Managing Director and Co-Founder, Toucan Capital
- Dr Werner Wolf, Venture Partner, TVM Capital
- Michael D Goldberg, General Partner, Mohr, Davidow Ventures
Legal
- Ivor Elrifi, Senior Partner, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo
- Julian Hitchcock, Senior Solicitor, Mills & Reeves
- James Lawford Davies, Solicitor, Bevan-Brittan and University of Newcastle
- Julian Crump, Member, Intellectual Property Section and Head, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo
|
|
